Heska (NASDAQ:HSKA) Shares Up 7.1%

Heska Co. (NASDAQ:HSKAGet Rating) shares shot up 7.1% during trading on Tuesday . The company traded as high as $100.57 and last traded at $99.95. 1,147 shares were traded during trading, a decline of 99% from the average session volume of 96,270 shares. The stock had previously closed at $93.32.

A number of research firms have recently commented on HSKA. Piper Sandler cut their target price on Heska from $190.00 to $180.00 and set a “na” rating on the stock in a research note on Sunday. TheStreet cut Heska from a “c-” rating to a “d+” rating in a research note on Friday, February 11th. Morgan Stanley dropped their price objective on Heska from $190.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 1st. Alliance Global Partners dropped their price objective on Heska from $240.00 to $150.00 in a research note on Tuesday, May 10th. Finally, JPMorgan Chase & Co. dropped their price objective on Heska from $300.00 to $250.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Heska presently has a consensus rating of “Hold” and a consensus target price of $219.00.

The business has a fifty day simple moving average of $129.23 and a two-hundred day simple moving average of $148.16. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.73 and a quick ratio of 5.37. The company has a market cap of $1.10 billion, a PE ratio of -79.53 and a beta of 1.64.

Heska (NASDAQ:HSKAGet Rating) last issued its quarterly earnings data on Monday, May 9th. The medical research company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.11 by $0.16. Heska had a negative return on equity of 0.95% and a negative net margin of 5.04%. The firm had revenue of $64.80 million during the quarter, compared to analyst estimates of $66.32 million. During the same quarter in the prior year, the business posted $0.20 EPS. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, equities research analysts predict that Heska Co. will post 0.6 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC lifted its holdings in shares of Heska by 1.7% during the 3rd quarter. Voya Investment Management LLC now owns 3,740 shares of the medical research company’s stock valued at $967,000 after purchasing an additional 62 shares during the last quarter. Maryland State Retirement & Pension System raised its stake in Heska by 1.9% in the 4th quarter. Maryland State Retirement & Pension System now owns 4,270 shares of the medical research company’s stock worth $779,000 after acquiring an additional 81 shares during the last quarter. Rhumbline Advisers raised its stake in Heska by 0.4% in the 4th quarter. Rhumbline Advisers now owns 23,386 shares of the medical research company’s stock worth $4,268,000 after acquiring an additional 85 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in Heska by 2.0% in the 4th quarter. Louisiana State Employees Retirement System now owns 5,200 shares of the medical research company’s stock worth $949,000 after acquiring an additional 100 shares during the last quarter. Finally, Truist Financial Corp raised its stake in Heska by 3.0% in the 3rd quarter. Truist Financial Corp now owns 3,489 shares of the medical research company’s stock worth $902,000 after acquiring an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Heska Company Profile (NASDAQ:HSKA)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Read More

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.